nodes	percent_of_prediction	percent_of_DWPC	metapath
Donepezil—CYP2D6—Hydroxyurea—psoriasis	0.0657	0.132	CbGbCtD
Donepezil—CYP3A4—Calcitriol—psoriasis	0.0491	0.099	CbGbCtD
Donepezil—CYP2C9—Cholecalciferol—psoriasis	0.0435	0.0877	CbGbCtD
Donepezil—CYP2D6—Cholecalciferol—psoriasis	0.0398	0.0802	CbGbCtD
Donepezil—CYP3A4—Methoxsalen—psoriasis	0.0382	0.077	CbGbCtD
Donepezil—CYP2C9—Cyclosporine—psoriasis	0.0286	0.0576	CbGbCtD
Donepezil—CYP2D6—Cyclosporine—psoriasis	0.0261	0.0527	CbGbCtD
Donepezil—CYP3A4—Cholecalciferol—psoriasis	0.0253	0.051	CbGbCtD
Donepezil—CYP3A4—Triamcinolone—psoriasis	0.0219	0.0442	CbGbCtD
Donepezil—CYP3A4—Mycophenolate mofetil—psoriasis	0.0219	0.0442	CbGbCtD
Donepezil—CYP2C9—Dexamethasone—psoriasis	0.0188	0.0379	CbGbCtD
Donepezil—CYP3A4—Betamethasone—psoriasis	0.0188	0.0379	CbGbCtD
Donepezil—CYP3A4—Prednisolone—psoriasis	0.0186	0.0374	CbGbCtD
Donepezil—CYP3A4—Hydrocortisone—psoriasis	0.0176	0.0355	CbGbCtD
Donepezil—CYP3A4—Prednisone—psoriasis	0.0175	0.0353	CbGbCtD
Donepezil—CYP2D6—Dexamethasone—psoriasis	0.0172	0.0347	CbGbCtD
Donepezil—CYP3A4—Cyclosporine—psoriasis	0.0166	0.0335	CbGbCtD
Donepezil—CYP3A4—Dexamethasone—psoriasis	0.0109	0.0221	CbGbCtD
Donepezil—Moexipril—ACE—psoriasis	0.00349	1	CrCbGaD
Donepezil—SIGMAR1—Levonorgestrel—Hydrocortisone—psoriasis	0.00187	1	CbGdCrCtD
Donepezil—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000888	0.0623	CbGpPWpGaD
Donepezil—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000881	0.0617	CbGpPWpGaD
Donepezil—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000829	0.0581	CbGpPWpGaD
Donepezil—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000551	0.0386	CbGpPWpGaD
Donepezil—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000546	0.0383	CbGpPWpGaD
Donepezil—ACHE—ATF-2 transcription factor network—IL23A—psoriasis	0.000504	0.0353	CbGpPWpGaD
Donepezil—HRH3—G alpha (i) signalling events—HCAR2—psoriasis	0.000432	0.0303	CbGpPWpGaD
Donepezil—HTR2A—Serotonin Receptor 2 and STAT3 Signaling—STAT3—psoriasis	0.00042	0.0294	CbGpPWpGaD
Donepezil—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00036	0.0252	CbGpPWpGaD
Donepezil—ACHE—Synthesis, secretion, and deacylation of Ghrelin—LEP—psoriasis	0.000357	0.025	CbGpPWpGaD
Donepezil—HRH3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000344	0.0241	CbGpPWpGaD
Donepezil—HRH3—GPCR ligand binding—HCAR2—psoriasis	0.000262	0.0183	CbGpPWpGaD
Donepezil—ACHE—Peptide hormone metabolism—REN—psoriasis	0.000254	0.0178	CbGpPWpGaD
Donepezil—ACHE—Melatonin metabolism and effects—APOE—psoriasis	0.000233	0.0163	CbGpPWpGaD
Donepezil—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000229	0.016	CbGpPWpGaD
Donepezil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000227	0.0159	CbGpPWpGaD
Donepezil—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000226	0.0158	CbGpPWpGaD
Donepezil—HRH3—G alpha (i) signalling events—CCL20—psoriasis	0.000224	0.0157	CbGpPWpGaD
Donepezil—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000224	0.0157	CbGpPWpGaD
Donepezil—HRH3—Monoamine Transport—TNF—psoriasis	0.000208	0.0146	CbGpPWpGaD
Donepezil—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000185	0.013	CbGpPWpGaD
Donepezil—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000184	0.0129	CbGpPWpGaD
Donepezil—HRH3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000178	0.0125	CbGpPWpGaD
Donepezil—ACHE—Peptide hormone metabolism—ACE—psoriasis	0.000159	0.0111	CbGpPWpGaD
Donepezil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000149	0.0105	CbGpPWpGaD
Donepezil—HRH3—GPCR downstream signaling—HCAR2—psoriasis	0.000148	0.0104	CbGpPWpGaD
Donepezil—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000148	0.0103	CbGpPWpGaD
Donepezil—ACHE—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.00014	0.00982	CbGpPWpGaD
Donepezil—ACHE—Melatonin metabolism and effects—NFKB1—psoriasis	0.000138	0.0097	CbGpPWpGaD
Donepezil—HRH3—GPCR ligand binding—CCL20—psoriasis	0.000136	0.00952	CbGpPWpGaD
Donepezil—HRH3—Signaling by GPCR—HCAR2—psoriasis	0.000134	0.00941	CbGpPWpGaD
Donepezil—ACHE—ATF-2 transcription factor network—NOS2—psoriasis	0.000123	0.00861	CbGpPWpGaD
Donepezil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000121	0.00849	CbGpPWpGaD
Donepezil—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00012	0.00838	CbGpPWpGaD
Donepezil—HTR2A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000114	0.00797	CbGpPWpGaD
Donepezil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000104	0.0073	CbGpPWpGaD
Donepezil—HTR2A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000103	0.00723	CbGpPWpGaD
Donepezil—Insomnia—Hydrocortisone—psoriasis	0.000101	0.000208	CcSEcCtD
Donepezil—Hypertension—Betamethasone—psoriasis	0.000101	0.000208	CcSEcCtD
Donepezil—Hypertension—Dexamethasone—psoriasis	0.000101	0.000208	CcSEcCtD
Donepezil—Paraesthesia—Hydrocortisone—psoriasis	0.0001	0.000207	CcSEcCtD
Donepezil—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.0001	0.000207	CcSEcCtD
Donepezil—Urticaria—Cyclosporine—psoriasis	9.97e-05	0.000206	CcSEcCtD
Donepezil—ACHE—Monoamine Transport—TNF—psoriasis	9.95e-05	0.00697	CbGpPWpGaD
Donepezil—Myalgia—Betamethasone—psoriasis	9.94e-05	0.000205	CcSEcCtD
Donepezil—Myalgia—Dexamethasone—psoriasis	9.94e-05	0.000205	CcSEcCtD
Donepezil—Abdominal pain—Cyclosporine—psoriasis	9.92e-05	0.000205	CcSEcCtD
Donepezil—Body temperature increased—Cyclosporine—psoriasis	9.92e-05	0.000205	CcSEcCtD
Donepezil—Anxiety—Betamethasone—psoriasis	9.91e-05	0.000205	CcSEcCtD
Donepezil—Anxiety—Dexamethasone—psoriasis	9.91e-05	0.000205	CcSEcCtD
Donepezil—Vomiting—Mycophenolic acid—psoriasis	9.87e-05	0.000204	CcSEcCtD
Donepezil—ACHE—Peptide hormone metabolism—LEP—psoriasis	9.85e-05	0.0069	CbGpPWpGaD
Donepezil—CYP2D6—Biological oxidations—CYP2S1—psoriasis	9.85e-05	0.0069	CbGpPWpGaD
Donepezil—Discomfort—Betamethasone—psoriasis	9.82e-05	0.000203	CcSEcCtD
Donepezil—Discomfort—Dexamethasone—psoriasis	9.82e-05	0.000203	CcSEcCtD
Donepezil—Dyspepsia—Hydrocortisone—psoriasis	9.82e-05	0.000203	CcSEcCtD
Donepezil—Haemoglobin—Methotrexate—psoriasis	9.82e-05	0.000203	CcSEcCtD
Donepezil—Rash—Mycophenolic acid—psoriasis	9.78e-05	0.000202	CcSEcCtD
Donepezil—Dermatitis—Mycophenolic acid—psoriasis	9.78e-05	0.000202	CcSEcCtD
Donepezil—Pain—Prednisolone—psoriasis	9.77e-05	0.000202	CcSEcCtD
Donepezil—Haemorrhage—Methotrexate—psoriasis	9.77e-05	0.000202	CcSEcCtD
Donepezil—Hepatitis—Methotrexate—psoriasis	9.77e-05	0.000202	CcSEcCtD
Donepezil—CYP2C9—Biological oxidations—CYP2S1—psoriasis	9.76e-05	0.00684	CbGpPWpGaD
Donepezil—Urticaria—Mycophenolate mofetil—psoriasis	9.73e-05	0.000201	CcSEcCtD
Donepezil—Headache—Mycophenolic acid—psoriasis	9.72e-05	0.000201	CcSEcCtD
Donepezil—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	9.71e-05	0.00681	CbGpPWpGaD
Donepezil—Decreased appetite—Hydrocortisone—psoriasis	9.7e-05	0.0002	CcSEcCtD
Donepezil—Pharyngitis—Methotrexate—psoriasis	9.69e-05	0.0002	CcSEcCtD
Donepezil—Abdominal pain—Mycophenolate mofetil—psoriasis	9.68e-05	0.0002	CcSEcCtD
Donepezil—Body temperature increased—Mycophenolate mofetil—psoriasis	9.68e-05	0.0002	CcSEcCtD
Donepezil—Urinary tract disorder—Methotrexate—psoriasis	9.64e-05	0.000199	CcSEcCtD
Donepezil—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.63e-05	0.000199	CcSEcCtD
Donepezil—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	9.63e-05	0.00675	CbGpPWpGaD
Donepezil—Fatigue—Hydrocortisone—psoriasis	9.62e-05	0.000199	CcSEcCtD
Donepezil—Vision blurred—Prednisone—psoriasis	9.59e-05	0.000198	CcSEcCtD
Donepezil—Urethral disorder—Methotrexate—psoriasis	9.57e-05	0.000198	CcSEcCtD
Donepezil—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.57e-05	0.000198	CcSEcCtD
Donepezil—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	9.55e-05	0.00669	CbGpPWpGaD
Donepezil—Pain—Hydrocortisone—psoriasis	9.54e-05	0.000197	CcSEcCtD
Donepezil—Oedema—Betamethasone—psoriasis	9.53e-05	0.000197	CcSEcCtD
Donepezil—Oedema—Dexamethasone—psoriasis	9.53e-05	0.000197	CcSEcCtD
Donepezil—Insomnia—Triamcinolone—psoriasis	9.5e-05	0.000196	CcSEcCtD
Donepezil—Infection—Betamethasone—psoriasis	9.47e-05	0.000196	CcSEcCtD
Donepezil—Infection—Dexamethasone—psoriasis	9.47e-05	0.000196	CcSEcCtD
Donepezil—Ill-defined disorder—Prednisone—psoriasis	9.44e-05	0.000195	CcSEcCtD
Donepezil—Paraesthesia—Triamcinolone—psoriasis	9.43e-05	0.000195	CcSEcCtD
Donepezil—ACHE—ATF-2 transcription factor network—IFNG—psoriasis	9.42e-05	0.0066	CbGpPWpGaD
Donepezil—Feeling abnormal—Prednisolone—psoriasis	9.41e-05	0.000195	CcSEcCtD
Donepezil—Visual impairment—Methotrexate—psoriasis	9.41e-05	0.000194	CcSEcCtD
Donepezil—Anaemia—Prednisone—psoriasis	9.4e-05	0.000194	CcSEcCtD
Donepezil—Shock—Dexamethasone—psoriasis	9.38e-05	0.000194	CcSEcCtD
Donepezil—Shock—Betamethasone—psoriasis	9.38e-05	0.000194	CcSEcCtD
Donepezil—Dyspnoea—Triamcinolone—psoriasis	9.37e-05	0.000194	CcSEcCtD
Donepezil—Nervous system disorder—Dexamethasone—psoriasis	9.35e-05	0.000193	CcSEcCtD
Donepezil—Nervous system disorder—Betamethasone—psoriasis	9.35e-05	0.000193	CcSEcCtD
Donepezil—Agitation—Prednisone—psoriasis	9.35e-05	0.000193	CcSEcCtD
Donepezil—Thrombocytopenia—Dexamethasone—psoriasis	9.33e-05	0.000193	CcSEcCtD
Donepezil—Thrombocytopenia—Betamethasone—psoriasis	9.33e-05	0.000193	CcSEcCtD
Donepezil—Hypersensitivity—Cyclosporine—psoriasis	9.25e-05	0.000191	CcSEcCtD
Donepezil—Dyspepsia—Triamcinolone—psoriasis	9.25e-05	0.000191	CcSEcCtD
Donepezil—Nausea—Mycophenolic acid—psoriasis	9.22e-05	0.00019	CcSEcCtD
Donepezil—Hyperhidrosis—Dexamethasone—psoriasis	9.22e-05	0.00019	CcSEcCtD
Donepezil—Hyperhidrosis—Betamethasone—psoriasis	9.22e-05	0.00019	CcSEcCtD
Donepezil—Feeling abnormal—Hydrocortisone—psoriasis	9.19e-05	0.00019	CcSEcCtD
Donepezil—Malaise—Prednisone—psoriasis	9.17e-05	0.00019	CcSEcCtD
Donepezil—Vertigo—Prednisone—psoriasis	9.14e-05	0.000189	CcSEcCtD
Donepezil—Gastrointestinal pain—Hydrocortisone—psoriasis	9.12e-05	0.000188	CcSEcCtD
Donepezil—Syncope—Prednisone—psoriasis	9.12e-05	0.000188	CcSEcCtD
Donepezil—Tinnitus—Methotrexate—psoriasis	9.11e-05	0.000188	CcSEcCtD
Donepezil—Anorexia—Dexamethasone—psoriasis	9.09e-05	0.000188	CcSEcCtD
Donepezil—Anorexia—Betamethasone—psoriasis	9.09e-05	0.000188	CcSEcCtD
Donepezil—Urticaria—Prednisolone—psoriasis	9.08e-05	0.000188	CcSEcCtD
Donepezil—Fatigue—Triamcinolone—psoriasis	9.06e-05	0.000187	CcSEcCtD
Donepezil—Hypersensitivity—Mycophenolate mofetil—psoriasis	9.02e-05	0.000186	CcSEcCtD
Donepezil—Asthenia—Cyclosporine—psoriasis	9.01e-05	0.000186	CcSEcCtD
Donepezil—Pain—Triamcinolone—psoriasis	8.98e-05	0.000186	CcSEcCtD
Donepezil—Loss of consciousness—Prednisone—psoriasis	8.94e-05	0.000185	CcSEcCtD
Donepezil—Hypotension—Dexamethasone—psoriasis	8.91e-05	0.000184	CcSEcCtD
Donepezil—Hypotension—Betamethasone—psoriasis	8.91e-05	0.000184	CcSEcCtD
Donepezil—Pruritus—Cyclosporine—psoriasis	8.88e-05	0.000184	CcSEcCtD
Donepezil—Urticaria—Hydrocortisone—psoriasis	8.86e-05	0.000183	CcSEcCtD
Donepezil—Abdominal pain—Hydrocortisone—psoriasis	8.82e-05	0.000182	CcSEcCtD
Donepezil—Body temperature increased—Hydrocortisone—psoriasis	8.82e-05	0.000182	CcSEcCtD
Donepezil—Convulsion—Prednisone—psoriasis	8.81e-05	0.000182	CcSEcCtD
Donepezil—Asthenia—Mycophenolate mofetil—psoriasis	8.79e-05	0.000182	CcSEcCtD
Donepezil—Hypertension—Prednisone—psoriasis	8.78e-05	0.000181	CcSEcCtD
Donepezil—ACHE—ATF-2 transcription factor network—CXCL8—psoriasis	8.76e-05	0.00614	CbGpPWpGaD
Donepezil—Chills—Methotrexate—psoriasis	8.76e-05	0.000181	CcSEcCtD
Donepezil—Musculoskeletal discomfort—Betamethasone—psoriasis	8.68e-05	0.000179	CcSEcCtD
Donepezil—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.68e-05	0.000179	CcSEcCtD
Donepezil—Pruritus—Mycophenolate mofetil—psoriasis	8.66e-05	0.000179	CcSEcCtD
Donepezil—HTR2A—GPCR ligand binding—HCAR2—psoriasis	8.66e-05	0.00607	CbGpPWpGaD
Donepezil—Myalgia—Prednisone—psoriasis	8.66e-05	0.000179	CcSEcCtD
Donepezil—Arthralgia—Prednisone—psoriasis	8.66e-05	0.000179	CcSEcCtD
Donepezil—Feeling abnormal—Triamcinolone—psoriasis	8.66e-05	0.000179	CcSEcCtD
Donepezil—Anxiety—Prednisone—psoriasis	8.63e-05	0.000178	CcSEcCtD
Donepezil—Alopecia—Methotrexate—psoriasis	8.63e-05	0.000178	CcSEcCtD
Donepezil—Insomnia—Betamethasone—psoriasis	8.62e-05	0.000178	CcSEcCtD
Donepezil—Insomnia—Dexamethasone—psoriasis	8.62e-05	0.000178	CcSEcCtD
Donepezil—Diarrhoea—Cyclosporine—psoriasis	8.59e-05	0.000177	CcSEcCtD
Donepezil—Paraesthesia—Dexamethasone—psoriasis	8.56e-05	0.000177	CcSEcCtD
Donepezil—Paraesthesia—Betamethasone—psoriasis	8.56e-05	0.000177	CcSEcCtD
Donepezil—Discomfort—Prednisone—psoriasis	8.56e-05	0.000177	CcSEcCtD
Donepezil—Mental disorder—Methotrexate—psoriasis	8.56e-05	0.000177	CcSEcCtD
Donepezil—Malnutrition—Methotrexate—psoriasis	8.5e-05	0.000176	CcSEcCtD
Donepezil—Erythema—Methotrexate—psoriasis	8.5e-05	0.000176	CcSEcCtD
Donepezil—Hypersensitivity—Prednisolone—psoriasis	8.42e-05	0.000174	CcSEcCtD
Donepezil—Dyspepsia—Betamethasone—psoriasis	8.39e-05	0.000173	CcSEcCtD
Donepezil—Dyspepsia—Dexamethasone—psoriasis	8.39e-05	0.000173	CcSEcCtD
Donepezil—Diarrhoea—Mycophenolate mofetil—psoriasis	8.38e-05	0.000173	CcSEcCtD
Donepezil—Urticaria—Triamcinolone—psoriasis	8.35e-05	0.000172	CcSEcCtD
Donepezil—Dysgeusia—Methotrexate—psoriasis	8.32e-05	0.000172	CcSEcCtD
Donepezil—Body temperature increased—Triamcinolone—psoriasis	8.31e-05	0.000172	CcSEcCtD
Donepezil—Dizziness—Cyclosporine—psoriasis	8.3e-05	0.000172	CcSEcCtD
Donepezil—Oedema—Prednisone—psoriasis	8.3e-05	0.000172	CcSEcCtD
Donepezil—Decreased appetite—Dexamethasone—psoriasis	8.29e-05	0.000171	CcSEcCtD
Donepezil—Decreased appetite—Betamethasone—psoriasis	8.29e-05	0.000171	CcSEcCtD
Donepezil—Infection—Prednisone—psoriasis	8.25e-05	0.00017	CcSEcCtD
Donepezil—Gastrointestinal disorder—Betamethasone—psoriasis	8.23e-05	0.00017	CcSEcCtD
Donepezil—Gastrointestinal disorder—Dexamethasone—psoriasis	8.23e-05	0.00017	CcSEcCtD
Donepezil—Back pain—Methotrexate—psoriasis	8.22e-05	0.00017	CcSEcCtD
Donepezil—Hypersensitivity—Hydrocortisone—psoriasis	8.22e-05	0.00017	CcSEcCtD
Donepezil—Fatigue—Betamethasone—psoriasis	8.22e-05	0.00017	CcSEcCtD
Donepezil—Fatigue—Dexamethasone—psoriasis	8.22e-05	0.00017	CcSEcCtD
Donepezil—Shock—Prednisone—psoriasis	8.17e-05	0.000169	CcSEcCtD
Donepezil—Pain—Betamethasone—psoriasis	8.15e-05	0.000168	CcSEcCtD
Donepezil—Pain—Dexamethasone—psoriasis	8.15e-05	0.000168	CcSEcCtD
Donepezil—ACHE—ATF-2 transcription factor network—JUN—psoriasis	8.15e-05	0.00571	CbGpPWpGaD
Donepezil—HTR2A—SIDS Susceptibility Pathways—IL13—psoriasis	8.14e-05	0.00571	CbGpPWpGaD
Donepezil—Nervous system disorder—Prednisone—psoriasis	8.14e-05	0.000168	CcSEcCtD
Donepezil—Dizziness—Mycophenolate mofetil—psoriasis	8.1e-05	0.000167	CcSEcCtD
Donepezil—Hyperhidrosis—Prednisone—psoriasis	8.03e-05	0.000166	CcSEcCtD
Donepezil—Vision blurred—Methotrexate—psoriasis	8.01e-05	0.000166	CcSEcCtD
Donepezil—Asthenia—Hydrocortisone—psoriasis	8.01e-05	0.000165	CcSEcCtD
Donepezil—Vomiting—Cyclosporine—psoriasis	7.98e-05	0.000165	CcSEcCtD
Donepezil—HRH3—Signaling Pathways—HCAR2—psoriasis	7.93e-05	0.00556	CbGpPWpGaD
Donepezil—Rash—Cyclosporine—psoriasis	7.92e-05	0.000164	CcSEcCtD
Donepezil—Anorexia—Prednisone—psoriasis	7.91e-05	0.000163	CcSEcCtD
Donepezil—Dermatitis—Cyclosporine—psoriasis	7.91e-05	0.000163	CcSEcCtD
Donepezil—Pruritus—Hydrocortisone—psoriasis	7.89e-05	0.000163	CcSEcCtD
Donepezil—Ill-defined disorder—Methotrexate—psoriasis	7.89e-05	0.000163	CcSEcCtD
Donepezil—Headache—Cyclosporine—psoriasis	7.86e-05	0.000162	CcSEcCtD
Donepezil—Anaemia—Methotrexate—psoriasis	7.86e-05	0.000162	CcSEcCtD
Donepezil—Feeling abnormal—Dexamethasone—psoriasis	7.86e-05	0.000162	CcSEcCtD
Donepezil—Feeling abnormal—Betamethasone—psoriasis	7.86e-05	0.000162	CcSEcCtD
Donepezil—Gastrointestinal pain—Betamethasone—psoriasis	7.8e-05	0.000161	CcSEcCtD
Donepezil—Gastrointestinal pain—Dexamethasone—psoriasis	7.8e-05	0.000161	CcSEcCtD
Donepezil—Vomiting—Mycophenolate mofetil—psoriasis	7.79e-05	0.000161	CcSEcCtD
Donepezil—Hypersensitivity—Triamcinolone—psoriasis	7.74e-05	0.00016	CcSEcCtD
Donepezil—Rash—Mycophenolate mofetil—psoriasis	7.72e-05	0.00016	CcSEcCtD
Donepezil—Dermatitis—Mycophenolate mofetil—psoriasis	7.71e-05	0.000159	CcSEcCtD
Donepezil—HRH3—GPCR downstream signaling—CCL20—psoriasis	7.68e-05	0.00538	CbGpPWpGaD
Donepezil—Headache—Mycophenolate mofetil—psoriasis	7.67e-05	0.000159	CcSEcCtD
Donepezil—Malaise—Methotrexate—psoriasis	7.67e-05	0.000158	CcSEcCtD
Donepezil—Vertigo—Methotrexate—psoriasis	7.64e-05	0.000158	CcSEcCtD
Donepezil—Diarrhoea—Hydrocortisone—psoriasis	7.63e-05	0.000158	CcSEcCtD
Donepezil—Urticaria—Dexamethasone—psoriasis	7.57e-05	0.000156	CcSEcCtD
Donepezil—Urticaria—Betamethasone—psoriasis	7.57e-05	0.000156	CcSEcCtD
Donepezil—Musculoskeletal discomfort—Prednisone—psoriasis	7.56e-05	0.000156	CcSEcCtD
Donepezil—Dizziness—Prednisolone—psoriasis	7.55e-05	0.000156	CcSEcCtD
Donepezil—Asthenia—Triamcinolone—psoriasis	7.54e-05	0.000156	CcSEcCtD
Donepezil—Body temperature increased—Betamethasone—psoriasis	7.54e-05	0.000156	CcSEcCtD
Donepezil—Abdominal pain—Betamethasone—psoriasis	7.54e-05	0.000156	CcSEcCtD
Donepezil—Body temperature increased—Dexamethasone—psoriasis	7.54e-05	0.000156	CcSEcCtD
Donepezil—Abdominal pain—Dexamethasone—psoriasis	7.54e-05	0.000156	CcSEcCtD
Donepezil—Insomnia—Prednisone—psoriasis	7.51e-05	0.000155	CcSEcCtD
Donepezil—Nausea—Cyclosporine—psoriasis	7.46e-05	0.000154	CcSEcCtD
Donepezil—Paraesthesia—Prednisone—psoriasis	7.45e-05	0.000154	CcSEcCtD
Donepezil—Pruritus—Triamcinolone—psoriasis	7.43e-05	0.000154	CcSEcCtD
Donepezil—Cough—Methotrexate—psoriasis	7.42e-05	0.000153	CcSEcCtD
Donepezil—Dizziness—Hydrocortisone—psoriasis	7.38e-05	0.000152	CcSEcCtD
Donepezil—Convulsion—Methotrexate—psoriasis	7.37e-05	0.000152	CcSEcCtD
Donepezil—Dyspepsia—Prednisone—psoriasis	7.31e-05	0.000151	CcSEcCtD
Donepezil—Nausea—Mycophenolate mofetil—psoriasis	7.27e-05	0.00015	CcSEcCtD
Donepezil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.26e-05	0.00509	CbGpPWpGaD
Donepezil—Chest pain—Methotrexate—psoriasis	7.24e-05	0.00015	CcSEcCtD
Donepezil—Myalgia—Methotrexate—psoriasis	7.24e-05	0.00015	CcSEcCtD
Donepezil—Arthralgia—Methotrexate—psoriasis	7.24e-05	0.00015	CcSEcCtD
Donepezil—Decreased appetite—Prednisone—psoriasis	7.22e-05	0.000149	CcSEcCtD
Donepezil—Rash—Prednisolone—psoriasis	7.2e-05	0.000149	CcSEcCtD
Donepezil—Dermatitis—Prednisolone—psoriasis	7.2e-05	0.000149	CcSEcCtD
Donepezil—Fatigue—Prednisone—psoriasis	7.16e-05	0.000148	CcSEcCtD
Donepezil—Headache—Prednisolone—psoriasis	7.16e-05	0.000148	CcSEcCtD
Donepezil—Discomfort—Methotrexate—psoriasis	7.15e-05	0.000148	CcSEcCtD
Donepezil—Constipation—Prednisone—psoriasis	7.1e-05	0.000147	CcSEcCtD
Donepezil—Vomiting—Hydrocortisone—psoriasis	7.09e-05	0.000147	CcSEcCtD
Donepezil—Rash—Hydrocortisone—psoriasis	7.04e-05	0.000145	CcSEcCtD
Donepezil—Dermatitis—Hydrocortisone—psoriasis	7.03e-05	0.000145	CcSEcCtD
Donepezil—Confusional state—Methotrexate—psoriasis	7e-05	0.000145	CcSEcCtD
Donepezil—Headache—Hydrocortisone—psoriasis	6.99e-05	0.000144	CcSEcCtD
Donepezil—HRH3—Signaling by GPCR—CCL20—psoriasis	6.97e-05	0.00489	CbGpPWpGaD
Donepezil—Dizziness—Triamcinolone—psoriasis	6.95e-05	0.000144	CcSEcCtD
Donepezil—Infection—Methotrexate—psoriasis	6.89e-05	0.000142	CcSEcCtD
Donepezil—HRH3—Signaling Pathways—TAGAP—psoriasis	6.88e-05	0.00482	CbGpPWpGaD
Donepezil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.87e-05	0.00481	CbGpPWpGaD
Donepezil—Feeling abnormal—Prednisone—psoriasis	6.84e-05	0.000141	CcSEcCtD
Donepezil—Asthenia—Betamethasone—psoriasis	6.84e-05	0.000141	CcSEcCtD
Donepezil—Asthenia—Dexamethasone—psoriasis	6.84e-05	0.000141	CcSEcCtD
Donepezil—Nervous system disorder—Methotrexate—psoriasis	6.8e-05	0.000141	CcSEcCtD
Donepezil—Thrombocytopenia—Methotrexate—psoriasis	6.79e-05	0.00014	CcSEcCtD
Donepezil—Gastrointestinal pain—Prednisone—psoriasis	6.79e-05	0.00014	CcSEcCtD
Donepezil—Nausea—Prednisolone—psoriasis	6.79e-05	0.00014	CcSEcCtD
Donepezil—Pruritus—Dexamethasone—psoriasis	6.74e-05	0.000139	CcSEcCtD
Donepezil—Pruritus—Betamethasone—psoriasis	6.74e-05	0.000139	CcSEcCtD
Donepezil—Hyperhidrosis—Methotrexate—psoriasis	6.71e-05	0.000139	CcSEcCtD
Donepezil—Vomiting—Triamcinolone—psoriasis	6.68e-05	0.000138	CcSEcCtD
Donepezil—Nausea—Hydrocortisone—psoriasis	6.63e-05	0.000137	CcSEcCtD
Donepezil—Rash—Triamcinolone—psoriasis	6.62e-05	0.000137	CcSEcCtD
Donepezil—Dermatitis—Triamcinolone—psoriasis	6.62e-05	0.000137	CcSEcCtD
Donepezil—Anorexia—Methotrexate—psoriasis	6.61e-05	0.000137	CcSEcCtD
Donepezil—Urticaria—Prednisone—psoriasis	6.59e-05	0.000136	CcSEcCtD
Donepezil—Headache—Triamcinolone—psoriasis	6.58e-05	0.000136	CcSEcCtD
Donepezil—Abdominal pain—Prednisone—psoriasis	6.56e-05	0.000136	CcSEcCtD
Donepezil—Body temperature increased—Prednisone—psoriasis	6.56e-05	0.000136	CcSEcCtD
Donepezil—Diarrhoea—Dexamethasone—psoriasis	6.52e-05	0.000135	CcSEcCtD
Donepezil—Diarrhoea—Betamethasone—psoriasis	6.52e-05	0.000135	CcSEcCtD
Donepezil—Hypotension—Methotrexate—psoriasis	6.48e-05	0.000134	CcSEcCtD
Donepezil—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.44e-05	0.00451	CbGpPWpGaD
Donepezil—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.35e-05	0.00445	CbGpPWpGaD
Donepezil—Musculoskeletal discomfort—Methotrexate—psoriasis	6.32e-05	0.000131	CcSEcCtD
Donepezil—Dizziness—Betamethasone—psoriasis	6.3e-05	0.00013	CcSEcCtD
Donepezil—Dizziness—Dexamethasone—psoriasis	6.3e-05	0.00013	CcSEcCtD
Donepezil—Insomnia—Methotrexate—psoriasis	6.28e-05	0.00013	CcSEcCtD
Donepezil—Nausea—Triamcinolone—psoriasis	6.24e-05	0.000129	CcSEcCtD
Donepezil—Paraesthesia—Methotrexate—psoriasis	6.23e-05	0.000129	CcSEcCtD
Donepezil—Dyspnoea—Methotrexate—psoriasis	6.19e-05	0.000128	CcSEcCtD
Donepezil—Somnolence—Methotrexate—psoriasis	6.17e-05	0.000127	CcSEcCtD
Donepezil—Hypersensitivity—Prednisone—psoriasis	6.12e-05	0.000126	CcSEcCtD
Donepezil—Dyspepsia—Methotrexate—psoriasis	6.11e-05	0.000126	CcSEcCtD
Donepezil—HRH3—G alpha (i) signalling events—CXCL8—psoriasis	6.06e-05	0.00425	CbGpPWpGaD
Donepezil—Vomiting—Dexamethasone—psoriasis	6.06e-05	0.000125	CcSEcCtD
Donepezil—Vomiting—Betamethasone—psoriasis	6.06e-05	0.000125	CcSEcCtD
Donepezil—Decreased appetite—Methotrexate—psoriasis	6.03e-05	0.000125	CcSEcCtD
Donepezil—Rash—Dexamethasone—psoriasis	6.01e-05	0.000124	CcSEcCtD
Donepezil—Rash—Betamethasone—psoriasis	6.01e-05	0.000124	CcSEcCtD
Donepezil—Dermatitis—Dexamethasone—psoriasis	6e-05	0.000124	CcSEcCtD
Donepezil—Dermatitis—Betamethasone—psoriasis	6e-05	0.000124	CcSEcCtD
Donepezil—Gastrointestinal disorder—Methotrexate—psoriasis	5.99e-05	0.000124	CcSEcCtD
Donepezil—Fatigue—Methotrexate—psoriasis	5.98e-05	0.000124	CcSEcCtD
Donepezil—Headache—Dexamethasone—psoriasis	5.97e-05	0.000123	CcSEcCtD
Donepezil—Headache—Betamethasone—psoriasis	5.97e-05	0.000123	CcSEcCtD
Donepezil—Asthenia—Prednisone—psoriasis	5.96e-05	0.000123	CcSEcCtD
Donepezil—Pain—Methotrexate—psoriasis	5.93e-05	0.000123	CcSEcCtD
Donepezil—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.91e-05	0.00414	CbGpPWpGaD
Donepezil—Pruritus—Prednisone—psoriasis	5.87e-05	0.000121	CcSEcCtD
Donepezil—Feeling abnormal—Methotrexate—psoriasis	5.72e-05	0.000118	CcSEcCtD
Donepezil—ACHE—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	5.71e-05	0.004	CbGpPWpGaD
Donepezil—Diarrhoea—Prednisone—psoriasis	5.68e-05	0.000117	CcSEcCtD
Donepezil—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	5.68e-05	0.00398	CbGpPWpGaD
Donepezil—Gastrointestinal pain—Methotrexate—psoriasis	5.67e-05	0.000117	CcSEcCtD
Donepezil—Nausea—Dexamethasone—psoriasis	5.66e-05	0.000117	CcSEcCtD
Donepezil—Nausea—Betamethasone—psoriasis	5.66e-05	0.000117	CcSEcCtD
Donepezil—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.55e-05	0.00389	CbGpPWpGaD
Donepezil—Urticaria—Methotrexate—psoriasis	5.51e-05	0.000114	CcSEcCtD
Donepezil—Dizziness—Prednisone—psoriasis	5.49e-05	0.000113	CcSEcCtD
Donepezil—Body temperature increased—Methotrexate—psoriasis	5.48e-05	0.000113	CcSEcCtD
Donepezil—Abdominal pain—Methotrexate—psoriasis	5.48e-05	0.000113	CcSEcCtD
Donepezil—Vomiting—Prednisone—psoriasis	5.28e-05	0.000109	CcSEcCtD
Donepezil—Rash—Prednisone—psoriasis	5.23e-05	0.000108	CcSEcCtD
Donepezil—Dermatitis—Prednisone—psoriasis	5.23e-05	0.000108	CcSEcCtD
Donepezil—Headache—Prednisone—psoriasis	5.2e-05	0.000107	CcSEcCtD
Donepezil—Hypersensitivity—Methotrexate—psoriasis	5.11e-05	0.000106	CcSEcCtD
Donepezil—HTR2A—SIDS Susceptibility Pathways—IL10—psoriasis	5.09e-05	0.00357	CbGpPWpGaD
Donepezil—Asthenia—Methotrexate—psoriasis	4.98e-05	0.000103	CcSEcCtD
Donepezil—Nausea—Prednisone—psoriasis	4.93e-05	0.000102	CcSEcCtD
Donepezil—ACHE—ATF-2 transcription factor network—IL6—psoriasis	4.92e-05	0.00345	CbGpPWpGaD
Donepezil—Pruritus—Methotrexate—psoriasis	4.91e-05	0.000101	CcSEcCtD
Donepezil—HTR2A—GPCR downstream signaling—HCAR2—psoriasis	4.9e-05	0.00343	CbGpPWpGaD
Donepezil—ACHE—Metabolism—NDUFA5—psoriasis	4.83e-05	0.00338	CbGpPWpGaD
Donepezil—HRH3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.82e-05	0.00338	CbGpPWpGaD
Donepezil—ACHE—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.8e-05	0.00336	CbGpPWpGaD
Donepezil—ACHE—Metabolism of proteins—REN—psoriasis	4.8e-05	0.00336	CbGpPWpGaD
Donepezil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.79e-05	0.00335	CbGpPWpGaD
Donepezil—Diarrhoea—Methotrexate—psoriasis	4.75e-05	9.81e-05	CcSEcCtD
Donepezil—Dizziness—Methotrexate—psoriasis	4.59e-05	9.48e-05	CcSEcCtD
Donepezil—ACHE—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.5e-05	0.00315	CbGpPWpGaD
Donepezil—HTR2A—GPCR ligand binding—CCL20—psoriasis	4.5e-05	0.00315	CbGpPWpGaD
Donepezil—HTR2A—Signaling by GPCR—HCAR2—psoriasis	4.45e-05	0.00312	CbGpPWpGaD
Donepezil—Vomiting—Methotrexate—psoriasis	4.41e-05	9.11e-05	CcSEcCtD
Donepezil—Rash—Methotrexate—psoriasis	4.37e-05	9.04e-05	CcSEcCtD
Donepezil—Dermatitis—Methotrexate—psoriasis	4.37e-05	9.03e-05	CcSEcCtD
Donepezil—Headache—Methotrexate—psoriasis	4.35e-05	8.98e-05	CcSEcCtD
Donepezil—Nausea—Methotrexate—psoriasis	4.12e-05	8.51e-05	CcSEcCtD
Donepezil—HRH3—Signaling Pathways—CCL20—psoriasis	4.12e-05	0.00289	CbGpPWpGaD
Donepezil—ACHE—Metabolism—CYP2S1—psoriasis	4.11e-05	0.00288	CbGpPWpGaD
Donepezil—HRH3—GPCR ligand binding—CXCL8—psoriasis	3.67e-05	0.00257	CbGpPWpGaD
Donepezil—ACHE—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.18e-05	0.00223	CbGpPWpGaD
Donepezil—ACHE—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.06e-05	0.00215	CbGpPWpGaD
Donepezil—ACHE—Metabolism of proteins—ACE—psoriasis	2.99e-05	0.0021	CbGpPWpGaD
Donepezil—HTR2A—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.79e-05	0.00195	CbGpPWpGaD
Donepezil—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.78e-05	0.00195	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—HCAR2—psoriasis	2.63e-05	0.00184	CbGpPWpGaD
Donepezil—HTR2A—SIDS Susceptibility Pathways—JUN—psoriasis	2.59e-05	0.00181	CbGpPWpGaD
Donepezil—HTR2A—GPCR downstream signaling—CCL20—psoriasis	2.54e-05	0.00178	CbGpPWpGaD
Donepezil—HTR2A—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.49e-05	0.00175	CbGpPWpGaD
Donepezil—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.47e-05	0.00173	CbGpPWpGaD
Donepezil—ACHE—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.38e-05	0.00167	CbGpPWpGaD
Donepezil—HTR2A—Signaling by GPCR—CCL20—psoriasis	2.31e-05	0.00162	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—TAGAP—psoriasis	2.28e-05	0.0016	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—SOCS1—psoriasis	2.27e-05	0.00159	CbGpPWpGaD
Donepezil—HTR2A—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.26e-05	0.00159	CbGpPWpGaD
Donepezil—HRH3—Signaling by GPCR—TYK2—psoriasis	2.16e-05	0.00152	CbGpPWpGaD
Donepezil—ACHE—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.15e-05	0.00151	CbGpPWpGaD
Donepezil—ACHE—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.1e-05	0.00147	CbGpPWpGaD
Donepezil—HRH3—GPCR downstream signaling—CXCL8—psoriasis	2.07e-05	0.00145	CbGpPWpGaD
Donepezil—ACHE—Metabolism—CARM1—psoriasis	2e-05	0.0014	CbGpPWpGaD
Donepezil—CYP2D6—Metabolism—NDUFA5—psoriasis	1.98e-05	0.00139	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism—NDUFA5—psoriasis	1.96e-05	0.00138	CbGpPWpGaD
Donepezil—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	1.94e-05	0.00136	CbGpPWpGaD
Donepezil—HRH3—Signaling by GPCR—CXCL8—psoriasis	1.88e-05	0.00132	CbGpPWpGaD
Donepezil—ACHE—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.87e-05	0.00131	CbGpPWpGaD
Donepezil—ACHE—Metabolism of proteins—LEP—psoriasis	1.86e-05	0.0013	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.83e-05	0.00128	CbGpPWpGaD
Donepezil—CYP2D6—Metabolism—CYP2S1—psoriasis	1.68e-05	0.00118	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—APOE—psoriasis	1.67e-05	0.00117	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—LEP—psoriasis	1.67e-05	0.00117	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism—CYP2S1—psoriasis	1.67e-05	0.00117	CbGpPWpGaD
Donepezil—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.6e-05	0.00112	CbGpPWpGaD
Donepezil—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	1.56e-05	0.0011	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—NFKBIA—psoriasis	1.56e-05	0.00109	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—CCL20—psoriasis	1.36e-05	0.000956	CbGpPWpGaD
Donepezil—CYP3A4—Metabolism—NDUFA5—psoriasis	1.29e-05	0.000907	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—TYK2—psoriasis	1.28e-05	0.000896	CbGpPWpGaD
Donepezil—ACHE—Metabolism of proteins—CXCL8—psoriasis	1.24e-05	0.000866	CbGpPWpGaD
Donepezil—ACHE—Metabolism—CAT—psoriasis	1.23e-05	0.000864	CbGpPWpGaD
Donepezil—HTR2A—GPCR ligand binding—CXCL8—psoriasis	1.22e-05	0.000852	CbGpPWpGaD
Donepezil—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.21e-05	0.000848	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—CXCL8—psoriasis	1.11e-05	0.00078	CbGpPWpGaD
Donepezil—CYP3A4—Metabolism—CYP2S1—psoriasis	1.1e-05	0.000772	CbGpPWpGaD
Donepezil—HRH3—Signaling by GPCR—IL6—psoriasis	1.06e-05	0.000741	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—JUN—psoriasis	1.03e-05	0.000725	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—NFKB1—psoriasis	9.96e-06	0.000698	CbGpPWpGaD
Donepezil—ACHE—Metabolism—APOE—psoriasis	9.58e-06	0.000671	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—VEGFA—psoriasis	9.04e-06	0.000633	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—STAT3—psoriasis	8.95e-06	0.000627	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.75e-06	0.000613	CbGpPWpGaD
Donepezil—ACHE—Metabolism—PPARG—psoriasis	8.35e-06	0.000585	CbGpPWpGaD
Donepezil—CYP2D6—Metabolism—CARM1—psoriasis	8.22e-06	0.000576	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism—CARM1—psoriasis	8.15e-06	0.000571	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.62e-06	0.000534	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—SOCS1—psoriasis	7.51e-06	0.000526	CbGpPWpGaD
Donepezil—HTR2A—Signaling by GPCR—TYK2—psoriasis	7.16e-06	0.000502	CbGpPWpGaD
Donepezil—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	6.87e-06	0.000481	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—TP53—psoriasis	6.83e-06	0.000479	CbGpPWpGaD
Donepezil—HRH3—Signaling Pathways—IL6—psoriasis	6.25e-06	0.000438	CbGpPWpGaD
Donepezil—HTR2A—Signaling by GPCR—CXCL8—psoriasis	6.24e-06	0.000437	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—LEP—psoriasis	5.54e-06	0.000388	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—APOE—psoriasis	5.54e-06	0.000388	CbGpPWpGaD
Donepezil—CYP3A4—Metabolism—CARM1—psoriasis	5.38e-06	0.000377	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—NFKBIA—psoriasis	5.17e-06	0.000362	CbGpPWpGaD
Donepezil—CYP2D6—Metabolism—CAT—psoriasis	5.06e-06	0.000354	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism—CAT—psoriasis	5.01e-06	0.000351	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—TYK2—psoriasis	4.23e-06	0.000296	CbGpPWpGaD
Donepezil—CYP2D6—Metabolism—APOE—psoriasis	3.93e-06	0.000275	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism—APOE—psoriasis	3.9e-06	0.000273	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—CXCL8—psoriasis	3.68e-06	0.000258	CbGpPWpGaD
Donepezil—HTR2A—Signaling by GPCR—IL6—psoriasis	3.5e-06	0.000245	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—JUN—psoriasis	3.42e-06	0.00024	CbGpPWpGaD
Donepezil—CYP2D6—Metabolism—PPARG—psoriasis	3.42e-06	0.00024	CbGpPWpGaD
Donepezil—CYP2C9—Metabolism—PPARG—psoriasis	3.39e-06	0.000238	CbGpPWpGaD
Donepezil—CYP3A4—Metabolism—CAT—psoriasis	3.31e-06	0.000232	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—NFKB1—psoriasis	3.3e-06	0.000231	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—VEGFA—psoriasis	2.99e-06	0.00021	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—STAT3—psoriasis	2.96e-06	0.000208	CbGpPWpGaD
Donepezil—CYP3A4—Metabolism—APOE—psoriasis	2.57e-06	0.00018	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—TP53—psoriasis	2.26e-06	0.000158	CbGpPWpGaD
Donepezil—CYP3A4—Metabolism—PPARG—psoriasis	2.24e-06	0.000157	CbGpPWpGaD
Donepezil—HTR2A—Signaling Pathways—IL6—psoriasis	2.07e-06	0.000145	CbGpPWpGaD
